ClinConnect ClinConnect Logo
Search / Trial NCT05901233

Speech-Language Treatment with Remotely Supervised Transcranial Direct Current Stimulation in Primary Progressive Aphasia

Launched by UNIVERSITY OF TEXAS AT AUSTIN · Jun 2, 2023

Trial Information

Current as of May 08, 2025

Active, not recruiting

Keywords

Speech Language Pathology Primary Progressive Aphasia Fronto Temporal Dementia Alzheimer's Disease Neurodegenerative Disease Logopenic Semantic Nonfluent Logopenic Variant Primary Progressive Aphasia Semantic Variant Primary Progressive Aphasia Nonfluent Variant Primary Progressive Aphasia Semantic Dementia Speech Entrainment Script Training Teletherapy Transcranial Direct Current Stimulation Remotely Supervised Transcranial Direct Current Stimulation Lexical Retrieval Noninvasive Brain Stimulation Telehealth

ClinConnect Summary

This clinical trial is studying a new treatment approach for people with Primary Progressive Aphasia (PPA), a condition that gradually affects a person’s ability to speak and communicate. The goal is to see if combining speech-language therapy delivered remotely with a special brain stimulation technique called transcranial direct current stimulation (tDCS) can help improve communication skills and overall quality of life for those living with PPA. The tDCS treatment is designed to be done at home, making it accessible and convenient for participants.

To be eligible for this study, individuals must have a confirmed diagnosis of PPA and be fluent in English. They should also have a study partner who can help them through the process and attend training sessions. Participants will need to have a good understanding of their mental abilities and will undergo a brain scan to ensure safety for the tDCS treatment. This trial is currently not recruiting new participants but aims to gather valuable information that could improve care for people with PPA in the future.

Gender

ALL

Eligibility criteria

  • Because PPA is a rare disease, the study aims to recruit all eligible participants with PPA who are referred to the Aphasia Research and Treatment Lab at the University of Texas (UT) Austin, the UT/Dell Medical School Department of Neurology, and the University of California at San Francisco (UCSF) Memory and Aging Center, as well as individuals with PPA from other clinical and research sites. The study will aim to include males, females, and transgender or non-binary individuals. Great efforts will be made to recruit participants from minority populations, subject to the limitation that participants need to be fluent speakers of English.
  • Inclusion Criteria:
  • Meets diagnostic criteria for PPA
  • Meets diagnostic criteria for a specific variant of PPA
  • Score of 20 or higher on the Mini-Mental State Examination
  • Adequate hearing and vision (with hearing or vision aids, if needed)
  • Has a study partner that can co-enroll in the study and attend pre-treatment training as well as continue to be present for weekly teleconference meetings
  • Able and willing to undergo MRI brain scan
  • Access to high speed internet
  • Exclusion Criteria:
  • Speech and language deficits better accounted for by another neurological disorder
  • Does not meet diagnostic criteria for a specific variant of PPA
  • Score of less than 20 on the Mini-Mental State Examination
  • Does not have a study partner who can co-enroll in the study
  • Contraindications for tDCS or MRI scan (History of seizures, head injury, craniotomy, skull surgery or fracture; History of severe or frequent migraines; Metallic implant in head or any metal in head; Pacemaker or cardioverter-defibrillator or any other stimulator; Chronic skin problems; Pregnancy)
  • History of stroke, epilepsy, or significant brain injury

About University Of Texas At Austin

The University of Texas at Austin, a leading research institution, is dedicated to advancing knowledge and innovation in the field of healthcare through rigorous clinical trials. Known for its commitment to scientific excellence, the university leverages its diverse expertise and cutting-edge facilities to conduct research that addresses critical health challenges. Collaborating with a multidisciplinary team of researchers, clinicians, and students, the University of Texas at Austin aims to translate scientific discoveries into effective treatments and interventions, ultimately enhancing patient outcomes and contributing to the advancement of medical science.

Locations

Austin, Texas, United States

San Francisco, California, United States

Patients applied

0 patients applied

Trial Officials

Maya Henry, PhD

Principal Investigator

University of Texas at Austin

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported